HeiQ Viroblock NPJ03 antiviral textile technology tested effective against Coronavirus

From left: Carlo Centonze, Dr. Thierry Pelet holding the first prototype of HeiQ Viroblock NPJ03 treated face masks (image provided by HeiQ) (PresseBox) ( Schlieren / Zurich, Switzerland, )
HeiQ, winner of the Swiss Technology Award and Swiss Environmental Award, launches HeiQ Viroblock NPJ03, an antiviral and antimicrobial textile treatment that is tested effective against coronavirus.

Since its inception 15 years ago, HeiQ has forged a solid innovation track record helping brands improve textile products. Catalyzed to action by the global fight against Coronavirus, HeiQ launches HeiQ Viroblock NPJ03, an antiviral and antimicrobial textile treatment which is proven effective against human coronavirus (229E) in face mask testing, significantly enhancing the antiviral log reduction from 2.90 of untreated face masks to 4.48, over 99.99% reduction of virus infectivity. (Remarks: a log reduction of 2 is equivalent to 100 times the effectiveness.)

“Virologist Dr. Thierry Pelet of HeiQ’s Scientific Advisory Board brought us a profound depth of knowledge and accelerated our efforts to address the urgent problem of a global pandemic”, says Carlo Centonze, HeiQ Group CEO.“Our goal is to prevent textiles from becoming a host surface for propagating harmful viruses and bacteria, and contribute to reduce the risk and speed of contamination and transmission.”

According to the World Health Organization, the incubation period for COVID-19 range from 1-14 days. Social distancing and wearing a mask are common measures that people in countries like South Korea and Taiwan take to avoid spreading the virus. Chinese protective masks producer Suzhou Bolisi is the lead adopter of HeiQ Viroblock NPJ03. Treated masks will be available on the market as early as this April. American legwear manufacturer Kayser-Roth is planning to add the technology to their new product, Ghluv hands protector, while Lufeng from China is evaluating the technology on other types of fabric used for garments.

I’m impressed by HeiQ’s ability to fast track such a complex innovation and bring this breakthrough to globally critical products in short time” said Dr. Pelet of HeiQ’s Scientific Advisory Board.

“HeiQ strives to help improve the lives of people through bringing breakthrough innovations to textiles. We have pushed hard to bring the HeiQ Viroblock technology to reality to assist at this time of urgent need for society around the world” adds Centonze.

HeiQ Viroblock NPJ03 is a unique combination of vesicle and silver technologies designed to inhibit the growth and persistence of bacteria and viruses. The HeiQ vesicle technology targets lipid-enveloped viruses, such as coronavirus, providing rapid virus deactivation, while the HeiQ silver technology inhibits the replication of both bacteria and viruses. HeiQ Viroblock NPJ03 can be applied to a wide spectrum of textile surfaces including face masks, air filters, medical gowns, curtains, drapes and more. HeiQ also has a range of highly wash-durable antimicrobial and odor control textile technologies, called HeiQ Pure, combining silver-based and bio-based materials for all fabric types.

Both 229E and Covid-19 are two of seven types of human coronaviruses. Besides testing on human coronavirus (229E), HeiQ Viroblock NPJ03 also demonstrates dramatically improved reduction of virus infectivity against Influenza types H1N1, H5N1, H7N9, and Respiratory Syncytial Virus (RSV).

For more information about Coronavirus, visit the CDC website. To learn more about Viroblock, email us at info@heiq.com.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.